Britain and America have signed a landmark bilateral deal that will maintain zero import taxes on UK medicine exports entering the American market.
The Terms of the Deal
Under the terms of the agreement, the UK has pledged to raise funding on medicines through the National Health Service (NHS). This pledge secures that tariffs on these key exports will stay at zero for a timeframe of 36 months.
This development comes after previous warnings to significantly raise duties on branded drug imports, with potential rates floated reaching double the cost.
"This agreement between the United Kingdom bolsters the global environment for innovative medicines and brings much-needed balance to U.S.–U.K. pharmaceutical trade," a release noted.
Trade Importance
Pharmaceuticals represent one of the the United Kingdom's biggest goods shipped to the US, which is easily the biggest destination for large British pharmaceutical firms.
Trade data indicate that in the year to the end of September, the UK shipped medicines totaling billions to the US. This amount accounted for a significant portion of total UK exports in that timeframe.
"This deal secures employment, stimulates capital expenditure and paves the way for the UK to emerge as a global hub for life sciences," a minister stated.
Specific NHS Changes
The agreement entails several specific changes from the UK:
- Revised Affordability Limit: The UK will raise the price threshold at which it considers new therapies to be too expensive by 25%.
- Boosted Medicine Funding: There is a goal to double overall NHS spending on treatments from 0.3% of the national economy to 0.6% over the following ten-year period.
- Rebate Cap: The percentage manufacturers must refund to the NHS to stay within budget will be capped at fifteen percent. In the past, refunds topped twenty percent.
Industry Background
The pact follows a long-running row between the pharmaceutical industry and the British authorities over medicine costs and regulatory access.
This friction were heightened by arguments that US consumers were paying significantly more for the same drugs than patients in the other developed nations.
In recent months, several significant pharmaceutical investments in the UK have been paused or scrapped, while substantial expansions have been announced toward US facilities.
A senior figure acknowledged that the NHS needed to spend more on drugs, noting that its expenditure on drugs had shrunk as a share of its overall budget over the last ten years.
